Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Aluise CD, Sowell RA, Butterfield DA.

Biochim Biophys Acta. 2008 Oct;1782(10):549-58. doi: 10.1016/j.bbadis.2008.07.008. Epub 2008 Aug 7. Review.

2.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
3.

Laboratory biomarkers in Alzheimer's disease.

Steinerman JR, Honig LS.

Curr Neurol Neurosci Rep. 2007 Sep;7(5):381-7. Review.

PMID:
17764627
4.

Biomarkers of Alzheimer's disease in body fluids.

Zheng Y, He J, Hong T.

Sci China Life Sci. 2010 Apr;53(4):490-6. doi: 10.1007/s11427-010-0081-9. Epub 2010 May 7. Review.

PMID:
20596916
5.

CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Rosenmann H.

J Mol Neurosci. 2012 May;47(1):1-14. doi: 10.1007/s12031-011-9665-5. Epub 2011 Nov 5. Review.

PMID:
22058061
6.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
7.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

8.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
9.

Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.

Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.

J Alzheimers Dis. 2014;42(3):777-88. doi: 10.3233/JAD-132216.

PMID:
24916543
10.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
11.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
12.

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, Kellmann M, Mullen W, Eichenlaub M, Mischak H, Wiedemann K.

PLoS One. 2011;6(10):e26540. doi: 10.1371/journal.pone.0026540. Epub 2011 Oct 26.

13.

A candidate plasma protein classifier to identify Alzheimer's disease.

Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj TC, Holder DJ, Dai H, Weiner R, Laterza OF.

J Alzheimers Dis. 2015;43(2):549-63. doi: 10.3233/JAD-141149.

PMID:
25114072
14.

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.

J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.

15.

[Biomarkers in Alzheimer's disease].

García-Ribas G, López-Sendón Moreno JL, García-Caldentey J.

Rev Neurol. 2014 Apr 1;58(7):308-17. Review. Spanish.

16.

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L.

Alzheimers Dement. 2014 Nov;10(6):808-17. doi: 10.1016/j.jalz.2014.03.003. Epub 2014 Aug 20.

PMID:
25150736
17.

Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Liu Y, Qing H, Deng Y.

Int J Mol Sci. 2014 May 6;15(5):7865-82. doi: 10.3390/ijms15057865. Review.

18.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
19.

[Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].

Verhey FR, Visser PJ.

Ned Tijdschr Geneeskd. 2013;157(11):A5596. Review. Dutch.

PMID:
23484512
20.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
Items per page

Supplemental Content

Write to the Help Desk